The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income | 197.9 | 153.7 | 209.5 | 115.4 |
| Stock-based compensation | 57.2 | 58.6 | 53.7 | 105.6 |
| Charges associated with convertible senior notes | - | 0 | 0 | 0 |
| Impairment charges associated with leased properties | - | 0 | 0.7 | - |
| Depreciation | 7.2 | 6.4 | 6.7 | 12.9 |
| Accretion of discount on available-for-sale debt securities, net | 1.3 | 2 | 2.7 | 8 |
| Impairment charges associated with leased properties | - | - | - | 0.7 |
| Amortization of acquired intangible assets | 0.1 | 1.1 | 1 | 2 |
| Changes in fair values of equity investments | 25.3 | 2.7 | 30.6 | -37.3 |
| Deferred income taxes | -61.1 | 48.2 | 168.3 | -51.1 |
| Non-cash lease expense | 2.7 | 5.9 | 6.6 | 14.3 |
| Gain on sale of business, net of transaction costs | 28.6 | - | - | - |
| Other | 0 | 0 | 0.2 | 0.5 |
| Accounts receivable | 81.4 | -38.4 | 132.3 | 116.6 |
| Inventory | -4.3 | 3.4 | 12.3 | -0.4 |
| Accounts payable and accrued liabilities | -14.3 | 76.5 | 55.8 | 27.9 |
| Income tax assets and liabilities | 119.8 | 35.5 | -54.3 | - |
| Other assets and liabilities, net | 31.4 | 27.8 | 42.1 | -25.5 |
| Cash flows from operating activities | 145.8 | 388.4 | 227.5 | 166.8 |
| Purchases of available-for-sale debt securities | 819.5 | 323 | 408.5 | 588.3 |
| Sales and maturities of available-for-sale debt securities | 259.2 | 267.7 | 225 | 596.7 |
| Purchases of equity investments | - | 0 | - | - |
| Proceeds from sale of business | 63.2 | - | - | - |
| Capital expenditures | 9.1 | -2.4 | 13.2 | 23.2 |
| Cash flows from investing activities | -506.2 | -52.9 | -196.7 | -14.8 |
| Payments to settle convertible senior notes | - | 0 | 0 | 0 |
| Issuances of common stock under benefit plans | 23.6 | 37.3 | 45.6 | 46.5 |
| Taxes paid related to net share settlement of equity awards | 55.7 | - | - | - |
| Repurchases of common stock | 54 | 0 | 0 | 167.7 |
| Cash flows from financing activities | -86.1 | 37.3 | 45.6 | -121.2 |
| Effect of exchange rate changes on cash and cash equivalents | - | 0 | -0.2 | 0.2 |
| Change in cash, cash equivalents and restricted cash | -446.5 | 372.8 | 76.2 | 31 |
| Cash, cash equivalents and restricted cash at beginning of period | 721 | 348.2 | 241 | - |
| Cash, cash equivalents and restricted cash at end of period | 274.5 | 721 | 348.2 | - |
NEUROCRINE BIOSCIENCES INC (NBIX)
NEUROCRINE BIOSCIENCES INC (NBIX)